A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Ipilimumab (Primary) ; Panobinostat (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 15 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.